Spironolactone Against Anthracycline-induced Cardiomyopathy

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study sought to investigate the whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: TC Erciyes University
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• LVEF >50%

• first diagnosed breast cancer

• female sex

Exclusion Criteria:

• Prior breast cancer and/or prior anthracycline exposure history

• LVEF <50%

• Use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers and beta blockers

• Creatinin value >2 mg/dl

• Presence of chronic kidney failure

• Potassium value >5.3 mg/dl

• Presence of adrenal gland diseases,

• Presence of severe liver failure

• Co-morbidities such as coronary heart disease, hypertension, atrial fibrillation, and valvular heart disease.

• Male patients were excluded for the homogenization of the study